Search Results - "Costantino, P."

Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS by WAPNIR, Irene L, DIGNAM, James J, WOLMARK, Norman, FISHER, Bernard, MAMOUNAS, Eleftherios P, ANDERSON, Stewart J, JULIAN, Thomas B, LAND, Stephanie R, MARGOLESE, Richard G, SWAIN, Sandra M, COSTANTINO, Joseph P

“…Ipsilateral breast tumor recurrence (IBTR) is the most common failure event after lumpectomy for ductal carcinoma in situ (DCIS). We evaluated invasive IBTR…”
Get full text

Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20 by Mamounas, Eleftherios P, Tang, Gong, Fisher, Bernard, Paik, Soonmyung, Shak, Steven, Costantino, Joseph P, Watson, Drew, Geyer, Jr, Charles E, Wickerham, D Lawrence, Wolmark, Norman

“…The 21-gene OncotypeDX recurrence score (RS) assay quantifies the risk of distant recurrence in tamoxifen-treated patients with node-negative, estrogen…”
Get full text

Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24 by CRAIG ALLRED, D, ANDERSON, Stewart J, LAND, Stephanie R, WOLMARK, Norman, PAIK, Soonmyung, LAWRENCE WICKERHAM, D, NAGTEGAAL, Iris D, SWAIN, Sandra M, MAMOUNAS, Elefetherios P, JULIAN, Thomas B, GEYER, Charles E, COSTANTINO, Joseph P

“…The NSABP (National Surgical Adjuvant Breast and Bowel Project) B-24 study demonstrated significant benefit with adjuvant tamoxifen in patients with ductal…”
Get full text

Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer by Paik, Soonmyung, Tang, Gong, Shak, Steven, Kim, Chungyeul, Baker, Joffre, Kim, Wanseop, Cronin, Maureen, Baehner, Frederick L, Watson, Drew, Bryant, John, Costantino, Joseph P, Geyer, Jr, Charles E, Wickerham, D Lawrence, Wolmark, Norman

“…The 21-gene recurrence score (RS) assay quantifies the likelihood of distant recurrence in women with estrogen receptor-positive, lymph node-negative breast…”
Get full text

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer by Tutt, Andrew N.J, Garber, Judy E, Kaufman, Bella, Viale, Giuseppe, Fumagalli, Debora, Rastogi, Priya, Gelber, Richard D, de Azambuja, Evandro, Fielding, Anitra, Balmaña, Judith, Domchek, Susan M, Gelmon, Karen A, Hollingsworth, Simon J, Korde, Larissa A, Linderholm, Barbro, Bandos, Hanna, Senkus, Elżbieta, Suga, Jennifer M, Shao, Zhimin, Pippas, Andrew W, Nowecki, Zbigniew, Huzarski, Tomasz, Ganz, Patricia A, Lucas, Peter C, Baker, Nigel, Loibl, Sibylle, McConnell, Robin, Piccart, Martine, Schmutzler, Rita, Steger, Guenther G, Costantino, Joseph P, Arahmani, Amal, Wolmark, Norman, McFadden, Eleanor, Karantza, Vassiliki, Lakhani, Sunil R, Yothers, Greg, Campbell, Christine, Geyer, Charles E

“…Among patients who had mutations in BRCA1 or BRCA2 and were at high risk for disease progression, those who were assigned to a year of olaparib adjuvant…”
Get full text

Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial by Krag, David N, Prof, Anderson, Stewart J, Prof, Julian, Thomas B, MD, Brown, Ann M, ScD, Harlow, Seth P, MD, Costantino, Joseph P, Prof, Ashikaga, Takamaru, Prof, Weaver, Donald L, Prof, Mamounas, Eleftherios P, Prof, Jalovec, Lynne M, MD, Frazier, Thomas G, Prof, Noyes, R Dirk, Prof, Robidoux, André, Prof, Scarth, Hugh MC, FRCSC, Wolmark, Norman, Prof

“…Summary Background Sentinel-lymph-node (SLN) surgery was designed to minimise the side-effects of lymph-node surgery but still offer outcomes equivalent to…”
Get full text

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data by Cuzick, Jack, Prof, Sestak, Ivana, PhD, Bonanni, Bernardo, MD, Costantino, Joseph P, DrPH, Cummings, Steve, MD, DeCensi, Andrea, Prof, Dowsett, Mitch, Prof, Forbes, John F, Prof, Ford, Leslie, MD, LaCroix, Andrea Z, Prof, Mershon, John, MD, Mitlak, Bruce H, MD, Powles, Trevor, Prof, Veronesi, Umberto, Prof, Vogel, Victor, Prof, Wickerham, D Lawrence, MD

“…Summary Background Tamoxifen and raloxifene reduce the risk of breast cancer in women at elevated risk of disease, but the duration of the effect is unknown…”
Get full text

Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer by ANDERSON, Stewart J, WAPNIR, Irene, DIGNAM, James J, FISHER, Bernard, MAMOUNAS, Eleftherios P, JEONG, Jong-Hyeon, GEYER, Charles E, WICKERHAM, D. Lawrence, COSTANTINO, Joseph P, WOLMARK, Norman

“…Locoregional failure (LRF) after breast-conserving therapy (BCT) is associated with increased risk of distant disease and death. The magnitude of this risk has…”
Get full text

Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older by Freedman, Andrew N, Yu, Binbing, Gail, Mitchell H, Costantino, Joseph P, Graubard, Barry I, Vogel, Victor G, Anderson, Garnet L, McCaskill-Stevens, Worta

“…The Study of Tamoxifen and Raloxifene (STAR) demonstrated that raloxifene was as effective as tamoxifen in reducing the risk of invasive breast cancer (IBC) in…”
Get full text

Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study by Fisher, Bernard, Costantino, Joseph P., Wickerham, D. Lawrence, Cecchini, Reena S., Cronin, Walter M., Robidoux, Andre, Bevers, Therese B., Kavanah, Maureen T., Atkins, James N., Margolese, Richard G., Runowicz, Carolyn D., James, Joan M., Ford, Leslie G., Wolmark, Norman

“…Background: Initial findings from the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial (P-1) demonstrated that tamoxifen…”
Get full text

Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection by Ashikaga, Takamaru, Krag, David N., Land, Stephanie R., Julian, Thomas B., Anderson, Stewart J., Brown, Ann M., Skelly, Joan M., Harlow, Seth P., Weaver, Donald L., Mamounas, Eleftherios P., Costantino, Joseph P., Wolmark, Norman

“…Background and Objectives Three year post‐surgical morbidity levels were compared between patients with negative sentinel lymph node dissection alone (SLND)…”
Get full text

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial by Robidoux, André, Prof, Tang, Gong, PhD, Rastogi, Priya, MD, Geyer, Charles E, Prof, Azar, Catherine A, MD, Atkins, James N, MD, Fehrenbacher, Louis, MD, Bear, Harry D, MD, Baez-Diaz, Louis, MD, Sarwar, Shakir, MD, Margolese, Richard G, MD, Farrar, William B, Prof, Brufsky, Adam M, Prof, Shibata, Henry R, Prof, Bandos, Hanna, PhD, Paik, Soonmyung, Prof, Costantino, Joseph P, Prof, Swain, Sandra M, Prof, Mamounas, Eleftherios P, Prof, Wolmark, Norman, Prof

“…Summary Background We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for trastuzumab in combination with weekly…”
Get full text

Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System by HUDIS, Clifford A, BARLOW, William E, ZUJEWSKI, Jo Anne, COSTANTINO, Joseph P, GRAY, Robert J, PRITCHARD, Kathleen I, CHAPMAN, Judith-Anne W, SPARANO, Joseph A, HUNSBERGER, Sally, ENOS, Rebecca A, GELBER, Richard D

“…Standardized definitions of breast cancer clinical trial end points must be adopted to permit the consistent interpretation and analysis of breast cancer…”
Get full text

Projecting Individualized Absolute Invasive Breast Cancer Risk in Asian and Pacific Islander American Women by Matsuno, Rayna K., Costantino, Joseph P., Ziegler, Regina G., Anderson, Garnet L., Li, Huilin, Pee, David, Gail, Mitchell H.

“…Background The Breast Cancer Risk Assessment Tool (BCRAT) of the National Cancer Institute is widely used for estimating absolute risk of invasive breast…”
Get full text

Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer by Swain, Sandra M, Jeong, Jong-Hyeon, Geyer, Charles E, Costantino, Joseph P, Pajon, Eduardo R, Fehrenbacher, Louis, Atkins, James N, Polikoff, Jonathan, Vogel, Victor G, Erban, John K, Rastogi, Priya, Livingston, Robert B, Perez, Edith A, Mamounas, Eleftherios P, Land, Stephanie R, Ganz, Patricia A, Wolmark, Norman

“…In node-positive breast cancer, adjuvant doxorubicin plus cyclophosphamide followed by docetaxel was associated with significantly better disease-free survival…”
Get full text

Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer by Kim, Rim S, Song, Nan, Gavin, Patrick G, Salgado, Roberto, Bandos, Hanna, Kos, Zuzana, Floris, Giuseppe, Eynden, Gert G G M Van den, Badve, Sunil, Demaria, Sandra, Rastogi, Priya, Fehrenbacher, Louis, Mamounas, Eleftherios P, Swain, Sandra M, Wickerham, D Lawrence, Costantino, Joseph P, Paik, Soonmyung, Wolmark, Norman, Geyer, Charles E, Lucas, Peter C, Pogue-Geile, Katherine L

“…Abstract We retrospectively assessed association of stromal tumor-infiltrating lymphocytes (sTILs) with clinical outcomes and molecular variables reportedly…”
Get full text

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer by Vogel, Victor G, Costantino, Joseph P, Wickerham, D Lawrence, Cronin, Walter M, Cecchini, Reena S, Atkins, James N, Bevers, Therese B, Fehrenbacher, Louis, Pajon, Eduardo R, Wade, 3rd, James L, Robidoux, André, Margolese, Richard G, James, Joan, Runowicz, Carolyn D, Ganz, Patricia A, Reis, Steven E, McCaskill-Stevens, Worta, Ford, Leslie G, Jordan, V Craig, Wolmark, Norman

“…The selective estrogen-receptor modulator (SERM) tamoxifen became the first U.S. Food and Drug Administration (FDA)-approved agent for reducing breast cancer…”
Get full text

Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor–Positive Breast Cancer: Recurrence Score Alone and Integrated With Pathologic and Clinical Factors by GONG TANG, CUZICK, Jack, COSTANTINO, Joseph P, DOWSETT, Mitch, FORBES, John F, CRAGER, Michael, MAMOUNAS, Eleftherios P, SHAK, Steven, WOLMARK, Norman

“…The 21-gene breast cancer assay recurrence score (RS) is widely used for assessing recurrence risk and predicting chemotherapy benefit in patients with…”
Get full text

Projecting Individualized Absolute Invasive Breast Cancer Risk in African American Women by Gail, Mitchell H., Costantino, Joseph P., Pee, David, Bondy, Melissa, Newman, Lisa, Selvan, Mano, Anderson, Garnet L., Malone, Kathleen E., Marchbanks, Polly A., McCaskill-Stevens, Worta, Norman, Sandra A., Simon, Michael S., Spirtas, Robert, Ursin, Giske, Bernstein, Leslie

“…Background The Breast Cancer Risk Assessment Tool of the National Cancer Institute (NCI) is widely used for counseling and determining eligibility for breast…”
Get full text

Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial by SWAIN, Sandra M, GONG TANG, BRUFSKY, Adam M, BIGGS, David D, LEVINE, Edward A, ZAPAS, John L, PROVENCHER, Louise, NORTHFELT, Donald W, PAIK, Soonmyung, COSTANTINO, Joseph P, MAMOUNAS, Eleftherios P, WOLMARK, Norman, GEYER, Charles E, RASTOGI, Priya, ATKINS, James N, DONNELLAN, Paul P, FEHRENBACHER, Louis, AZAR, Catherine A, ROBIDOUX, André, POLIKOFF, Jonathan A

“…Anthracycline- and taxane-based three-drug chemotherapy regimens have proven benefit as adjuvant therapy for early-stage breast cancer. This trial (NSABP B-38;…”
Get full text